このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

皮膚扁平上皮癌患者におけるL19IL2/L19TNF

2026年11月12日 更新者:Philogen S.p.A.

全身治療で進行中または不耐性の局所進行性皮膚扁平上皮癌患者におけるL19IL2/L19TNFの腫瘍内投与に関する第2相試験

Open-label, single-arm, multicenter study in patients with locally advanced, histologically confirmed Cutaneous Squamous Cell Carcinoma (LacSCC) amenable to intratumoral injection, who have progressed on or are intolerant to Immune Checkpoint Inhibitor (ICI). The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks: for those who have a partial response or stable disease as their best response, a second 4-week course L19IL2/L19TNF of four weekly injections may be administered as per treating physician judgement. Patients will be followed for a maximum of 160 weeks after beginning of treatment.

調査の概要

状態

募集

介入・治療

詳細な説明

Tumor Assessment (TA) visits will be performed at Week 8 (Day 50 from the beginning of treatment), Week 12 (Day 78), and then every 8 weeks for the first year of Follow-up (FU). During second and third years of FU, TA visits will be performed every 12 Weeks. In case a response (CR, PR) or stable disease is observed, a confirmatory assessment of the tumor response will be performed 4 weeks after the TA visit, when the response was first recorded.

Confirmation of response will be assessed by histopathological analysis of specimens from the skin treated area by multiple punch biopsies. Confirmation of tumor responses will be centrally reviewed by an independent committee (Independent Central Review, ICR).

Patients will be followed for overall survival (OS) after a relapse or progression, and any further treatment given will be recorded until LPLV. Phone contact or any other documented contact with the patient will be recorded every 6 months for OS assessment from treatment start until the death of the patient, withdrawal of consent or until study completion (LPLV).

L19IL2/L19TNF will be administered to eligible patients under the supervision of the investigator or identified sub-investigator(s). Patients will receive intratumoral administrations of L19IL2/L19TNF into injectable cutaneous, subcutaneous tumors and nodal or in transit metastasis once weekly for up to 4 weeks. On the day of each treatment visit, all tumors to be injected should be measured and recorded (using caliper/ruler for cutaneous lesions and/or ultrasound for subcutaneous lesions). The recommended volume to be injected into the tumor(s) is dependent on the size of the lesion(s). The maximum dose to be administered in a single treatment visit is: 13 MioIU L19IL2 + 0.4 mg L19TNF. It is recommended that each lesion should receive the maximum amount possible to inject due to tumor properties at each visit.

研究の種類

介入

入学 (推定)

92

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • California
      • Orange、California、アメリカ、92868-3201
        • 募集
        • UC Irvine Health- Chao Family Comprehensive Cancer Center
        • 主任研究者:
          • Maki MD Yamamoto
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • 募集
        • Winship Cancer Institute, Emory University
        • 主任研究者:
          • Michael C. Lowe, MD
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02215
        • 募集
        • Dana-Farber Cancer Institute
        • 主任研究者:
          • Emily Ruiz, MD
    • North Carolina
      • Durham、North Carolina、アメリカ、27710
        • 募集
        • Duke University Medical Center
        • 主任研究者:
          • Melodi J Whitley, MD
    • Ohio
      • Columbus、Ohio、アメリカ、43210
        • まだ募集していません
        • The Ohio State University Wexner Medical Center Clinical Laboratories
        • 主任研究者:
          • Carlo Contreras, MD
    • Texas
      • Houston、Texas、アメリカ、77030
        • 募集
        • The University of Texas MD Anderson Cancer Center
        • 主任研究者:
          • Michael R Migden, MD
      • Naples、イタリア、80131
        • 募集
        • IRCCS Istituto Nazionale Tumori Fondazione Pascale
        • 主任研究者:
          • Paolo Ascierto, Prof.
      • Roma、イタリア、00168
        • 募集
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
        • 主任研究者:
          • Ketty Peris, Prof.
      • Rozzano、イタリア、20089
        • 募集
        • Humanitas Mirasole S.p.A.
        • 主任研究者:
          • Paolo Bossi, Prof.
      • Siena、イタリア、53100
        • 募集
        • Azienda Ospedaliero-Universitaria Senese
        • 主任研究者:
          • Annamaria Di Giacomo, Prof.
      • Athens、ギリシャ、16121
        • まだ募集していません
        • Andreas Syngros Hospital Of Venereal And Dermatological Diseases
        • 主任研究者:
          • Alexandros Stratigos, Prof.
      • Barcelona、スペイン、08036
        • 募集
        • Hospital Clinic De Barcelona
        • 主任研究者:
          • Augustin Toll Abello
      • Augsburg、ドイツ、86179
        • 募集
        • Universitaetsklinikum Augsburg
        • 主任研究者:
          • Julia Welzel
      • Berlin、ドイツ、10117
        • 募集
        • Charite Universitaetsmedizin Berlin KöR
        • 主任研究者:
          • Thomas Eigentler, Prof.
      • Essen、ドイツ、45147
        • 募集
        • Universitaetsklinikum Essen AöR
        • 主任研究者:
          • Dirk Schadendorf, Prof.
      • Halle、ドイツ、06120
        • 募集
        • Universitaetsklinikum Halle (Saale) AöR
        • 主任研究者:
          • Johannes Wohlrab, Prof.
      • Heidelberg、ドイツ、69120
        • 募集
        • Universitaetsklinikum Heidelberg AöR
        • 主任研究者:
          • Jessica Hassel, Prof.
      • Kiel、ドイツ、24105
        • 募集
        • Universitaetsklinikum Schleswig-Holstein AöR
        • 主任研究者:
          • Katharina Kahler, Prof.
      • Tübingen、ドイツ、72076
        • 募集
        • Universitaetsklinikum Tübingen AöR
        • 主任研究者:
          • Lukas Flatz, Prof.

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Patients must have histologically documented, locally advanced cSCC.
  • Patients must have at least one injectable and measurable cutaneous or subcutaneous lesion.
  • Patients must have locally advanced cSCC that has progressed on or cannot tolerate ICI treatment (adjuvant or first line) as assessed by a local multidisciplinary tumor board.
  • Patients with nodal, regional or in transit injectable cSCC lesions.
  • Patients must be willing to provide tissue from a core or excisional biopsy of a tumor lesion at screening and for confirmation of Objective Response or Stable Disease.
  • Male or female patients, who are capable of giving consent, age ≥ 18 years.
  • ECOG Performance Status/WHO Performance Status ≤ 2.
  • Hemoglobin > 10.0 g/dL.
  • Platelets > 100 x 109/L.
  • ALT and AST, GGT and Lipase ≤ 1.5 x the upper limit of normal (ULN).
  • All acute toxic effects (excluding alopecia) of any prior therapy must have resolved to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v. 5.0) Grade ≤ 1 unless otherwise specified.
  • Women of childbearing potential (WOCBP) must have negative pregnancy test results at screening. WOCBP must be using, from screening to three months following the last study drug administration, highly effective contraception methods, as defined by the "Recommendations for contraception and pregnancy testing in clinical trials" issued by the Head of Medicine Agencies' Clinical Trial Facilitation Group and which include, for instance, progesterone-only or combined (estrogen- and progesterone-containing) hormonal contraception associated with inhibition of ovulation, intrauterine devices, intrauterine hormone-releasing systems, bilateral tubal occlusion, vasectomised partner.
  • Male patients with WOCBP partners must agree to use simultaneously two acceptable methods of contraception (i.e. spermicidal gel plus condom) from the screening to three months following the last study drug administration.
  • Willingness and ability to comply with the scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  • Presence of concomitant malignancies, with the exception of any cancer curatively treated more than 3 years prior to study entry and of tumors with a negligible risk for metastasis or death, such as adequately treated basal cell carcinoma of the skin (surgically removed at least 4 weeks prior to study entry), ductal carcinoma in situ of the breast, or carcinoma in situ of the cervix, early-stage asymptomatic CLL and not under active treatment (Rai 0, Binet A) will be eligible for the study.
  • Radiation therapy on the tumor sites in the 4 weeks prior to study drug administration.
  • Current topical or systemic chemotherapy, immunotherapy.
  • Presence of visceral metastasis.
  • disease/infection requiring therapy, including positive tests for human immunodeficiency virus (HIV)-1 or HIV-2 serum antibody, hepatitis B virus (HBV), or hepatitis C virus (HCV). For HBV serology, the determination of HBsAg and anti-HBcAg Ab is required. In patients with serology documenting previous exposure to HBV, negative serum HBV-DNA is required. For HCV, HCV-RNA or HCV antibody test is required. Subjects with a positive test for HCV antibody but no detection of HCV-RNA indicating no current infection are eligible.
  • History within the last year of acute or subacute coronary syndromes including myocardial infarction, unstable or severe stable angina pectoris, inadequately treated cardiac arrhythmias and heart insufficiency (any grade, New York Heart Association (NYHA) criteria).
  • Any abnormalities observed during baseline ECG investigations that are considered clinically significant by the investigator.
  • Known arterial aneurysms.
  • Chronically impaired renal function as indicated by creatinine clearance < 60 mL/min/1.73m2 or for patients older than 65 years without albuminuria or proteinuria, creatinine clearance < 45 mL/min/1.73m2.
  • INR > 3.
  • Uncontrolled hypertension.
  • Known uncontrolled coagulopathy or bleeding disorder.
  • Known hepatic cirrhosis or severe pre-existing hepatic impairment.
  • Moderate to severe respiratory failure.
  • Active autoimmune disease that has required systemic treatment in past 2 years.
  • Patients have a diagnosis of immunodeficiency or are receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug. Limited use of corticosteroids to treat or prevent acute hypersensitivity reactions and asthma/COPD is not considered an exclusion criterion.
  • Known history of allergy to IL2, TNF, or other human proteins/peptides/antibodies.
  • Pregnancy or breast-feeding.
  • Ischemic peripheral vascular disease (Grade IIb-IV).
  • Severe diabetic retinopathy.
  • Recovery from major trauma including surgery within 4 weeks prior to enrollment.
  • Solid organ transplant recipient or patient with iatrogenic or pathologic severe immune suppression.
  • Patients with a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
  • Patients who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed.
  • Any conditions that in the opinion of the investigator could hamper compliance with the study protocol.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Treatment

the patients will receive multiple intratumoral administrations of a mixture of L19IL2 and L19TNF to all injectable cutaneous and subcutaneous lesions once weekly for up to 4 weeks.

intratumoral administrations

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Overall Response Rate (BORR)
時間枠:From enrollment up to a maximum of 160 weeks after the start of treatment

Best Overall Response Rate (BORR) as defined by the RECIST 1.1. criteria according to an Independent Central Review (ICR).

From enrollment up to a maximum of 160 weeks after the start of treatment

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年10月29日

一次修了 (推定)

2031年2月1日

研究の完了 (推定)

2031年2月1日

試験登録日

最初に提出

2025年11月7日

QC基準を満たした最初の提出物

2025年11月11日

最初の投稿 (実際)

2025年11月14日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月13日

QC基準を満たした最後の更新が送信されました

2026年11月12日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • PH-L19IL2TNFSCC-06/24
  • 2025-523231-19-00 (Ctis)
  • 2025 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する